Drug Trial News

RSS

Advaxis reports continued positive patient survival pattern in ADXS-HPV Phase 2 cervical cancer trial

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, presented updated preliminary data from an ongoing randomized Phase 2 trial of ADXS-HPV being conducted in India in women with recurrent/refractory cervical cancer who have failed previous cytotoxic therapy.

30 Jul 2012

Early ART treatment delays AIDS-related health events in HIV-infected individuals

Further analyses of the landmark NIH-funded treatment-as-prevention study (HPTN 052) have found that providing antiretroviral treatment to HIV-infected individuals earlier, when their immune systems are healthier, delays AIDS-related health events, such as chronic herpes simplex virus and tuberculosis, as well as death. Additionally, researchers found that earlier HIV treatment is also cost-effective because it increases survival, prevents costly opportunistic infections and averts transmission of the virus to uninfected individuals.

30 Jul 2012

Scientists discover new way to combat post-surgical scarring for glaucoma patients

Scientists at the Singapore Eye Research Institute (SERI) and Nanyang Technological University (NTU) have developed an innovative way to combat post-surgical scarring for glaucoma patients.

30 Jul 2012

Paper highlights clinical and immunological activity of immatics’ IMA901 in renal cell carcinoma

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of its lead cancer vaccine, IMA901, have been published in Nature Medicine.

30 Jul 2012

Genentech's BREVACTA study of ACTEMRA on rheumatoid arthritis meets primary endpoint

Genentech, a member of the Roche Group, today announced that the BREVACTA study of ACTEMRA (tocilizumab) given as a subcutaneous (SC) injection to patients with rheumatoid arthritis (RA) met its primary endpoint.

28 Jul 2012

Economist articles, blog examine research presented at AIDS 2012 conference

The Economist on Friday published two articles from Saturday's print edition regarding the XIX International AIDS Conference (AIDS 2012). One article states that "few areas of international affairs have seen more recent success than the fight against AIDS," and discusses advancements in HIV treatment research and availability.

28 Jul 2012

Experimental dengue vaccine protects against 3 of 4 viral strains, study results show

"The world's first vaccine against dengue fever, being developed by French drugmaker Sanofi SA, protected against three of the virus's four strains in a keenly awaited clinical trial in Thailand," the company announced on Wednesday, Reuters reports.

28 Jul 2012

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

ARIAD Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 3 trial of ponatinib, its investigational pan-BCR-ABL inhibitor, in adult patients with newly diagnosed chronic myeloid leukemia (CML).

28 Jul 2012

Rituximab also benefits patients with kidney disorder

A drug commonly used to treat immune disorders such as lymphoma and arthritis also benefits patients with an immune disorder of the kidneys that can lead to kidney failure, according to a study appearing in an upcoming issue of new study in the Journal of the American Society of Nephrology (JASN).

28 Jul 2012

TB combination drug: an interview with Mel Spigelman, MD, CEO and President of TB Alliance

TB is a leading global killer. It is the second leading infectious disease in the world, behind HIV. TB is spread through the air, so it can affect anyone, but has its worst impact on impoverished communities and those people with HIV.

27 Jul 2012

Anakinra can dramatically limit amount of brain damage in stroke patients

Scientists led by the President of The University of Manchester have demonstrated a drug which can dramatically limit the amount of brain damage in stroke patients.

From The University of Manchester 27 Jul 2012

HPTN study results show additional benefits of early ART in HIV clinical outcomes

Study results released today by the HIV Prevention Trials Network (HPTN) show additional benefits of early antiretroviral therapy (ART) in HIV clinical outcomes.

27 Jul 2012

Navidea announces results from Lymphoseek Phase 3 trial on head and neck squamous cell carcinoma

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, noted today that individual site, investigator-initiated results of an ongoing Phase 3 clinical trial of 99m-Tc-Tilmanocept (Lymphoseek) were presented at the American Head and Neck Society's 8th International Conference on Head and Neck Cancer (ICHNC), held in Toronto, July 21-25, 2012.

27 Jul 2012

Preliminary findings from Protalex's PRTX-100 Phase 1b study on active rheumatoid arthritis

Protalex, Inc., a clinical stage biopharmaceutical company that is developing a class of drugs designed to treat a wide array of autoimmune and inflammatory diseases today announced preliminary findings from its recently completed Phase 1b randomized, multiple-dose, dose-escalation study.

26 Jul 2012

New association found between basal cell carcinoma and eczema

In the powerful sunlight of July, newly published results from a large study of people at high risk for basal cell carcinoma support the emerging view of the nation's most common cancer as a chronic ailment that often repeatedly afflicts older people but for which the seeds may be planted in youth. The research also found a new association with eczema.

26 Jul 2012

Raising dopamine levels in frontal cortex reduces impulsivity in healthy adults

Raising levels of the neurotransmitter dopamine in the frontal cortex of the brain significantly decreased impulsivity in healthy adults, in a study conducted by researchers at the Ernest Gallo Clinic and Research Center at the University of California, San Francisco.

26 Jul 2012

Bio-Path initiates enrollment in fourth cohort of Liposomal Grb-2 Phase I trial for blood cancers

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrolling patients into the fourth dosage cohort in its Phase I clinical trial of its lead product candidate, BP-100.1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).

26 Jul 2012

Multi-center clinical trial results demonstrate safety and efficacy of carfilzomib for multiple myeloma

Researchers from John Theurer Cancer Center at HackensackUMC, one of the nation's 50 best hospitals for cancer, played leading roles in three separate multi-center studies with the new proteasome inhibitor carfilzomib published in Blood, a major peer-reviewed scientific journal.

26 Jul 2012

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.

26 Jul 2012

Bard completes enrollment in Lutonix DCB clinical trial for peripheral arterial disease

C. R. Bard, Inc. today announced that its Lutonix technology center completed patient enrollment into its global, multicenter LEVANT 2 randomized clinical trial.

26 Jul 2012

Drug Trial News

Advaxis reports continued positive patient survival pattern in ADXS-HPV Phase 2 cervical cancer trial

Early ART treatment delays AIDS-related health events in HIV-infected individuals

Scientists discover new way to combat post-surgical scarring for glaucoma patients

Paper highlights clinical and immunological activity of immatics’ IMA901 in renal cell carcinoma

Genentech's BREVACTA study of ACTEMRA on rheumatoid arthritis meets primary endpoint

Economist articles, blog examine research presented at AIDS 2012 conference

Experimental dengue vaccine protects against 3 of 4 viral strains, study results show

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

Rituximab also benefits patients with kidney disorder

TB combination drug: an interview with Mel Spigelman, MD, CEO and President of TB Alliance

Anakinra can dramatically limit amount of brain damage in stroke patients

HPTN study results show additional benefits of early ART in HIV clinical outcomes

Navidea announces results from Lymphoseek Phase 3 trial on head and neck squamous cell carcinoma

Preliminary findings from Protalex's PRTX-100 Phase 1b study on active rheumatoid arthritis

New association found between basal cell carcinoma and eczema

Raising dopamine levels in frontal cortex reduces impulsivity in healthy adults

Bio-Path initiates enrollment in fourth cohort of Liposomal Grb-2 Phase I trial for blood cancers

Multi-center clinical trial results demonstrate safety and efficacy of carfilzomib for multiple myeloma

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

Bard completes enrollment in Lutonix DCB clinical trial for peripheral arterial disease

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News